Navigation Links
OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting
Date:9/23/2009

SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
2. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
3. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
4. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
5. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
8. ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimers disease clinical trials
9. Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   InspireMD, Inc.  ("InspireMD" or the ... systems ("EPS"), today announced that it has entered into ... million shares of common stock and warrants to purchase ... in a public offering.  The common stock will be ... share, and each purchaser will receive a warrant to ...
(Date:3/4/2015)... Israël, 4 mars 2015 /PRNewswire/ ... (« RedHill » ou la « Société »), une ... sur les spécialités pharmaceutiques administrés ... stade clinique avancé pour les ... notamment les cancers gastro-intestinaux, a ...
(Date:3/4/2015)... -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP ) announced today ... at the Ritz-Carlton at Laguna Niguel, California ... Arthur S. Przybyl , President and CEO, will give the ... ANI,s website at www.anipharmaceuticals.com . Mr. Przybyl,s presentation will ... available through the link through June 7, 2015. ...
Breaking Medicine Technology:InspireMD Announces Public Offering for Approximately $13.5 Million 2InspireMD Announces Public Offering for Approximately $13.5 Million 3InspireMD Announces Public Offering for Approximately $13.5 Million 4RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 2RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 3RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 4RedHill Biopharma présentera à l'événement en ligne sur VirtualInvestorConferences.com le 5 mars 2015 5ANI Pharmaceuticals To Present At 27th Annual ROTH Conference 2
... YORK, Jan. 12, 2011 NeoStem, Inc. (NYSE Amex: ... company with operations in the U.S. and China, today announced ... present on Wednesday, January 12, 2011 at the OneMedForum 2011 ... at 11:00 AM PST. Both events will be held in ...
... InstaCare Corp. (OTC Bulletin Board:  ISCR) a ... testing products for the chronically ill, a leading ... and a leading developer of revolutionary cell phone ... company,s Board of Directors has received the initial ...
Cached Medicine Technology:NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011 2NeoStem to Present at Two Investor Conferences in San Francisco on Wednesday, January 12, 2011 3InstaCare Corp. Announces 2011 Genstrip Guidance Report Penned by William Walling, CFA 2
(Date:3/4/2015)... Nitrosigine®, a patented complex of bonded arginine silicate ... is hosting the Nitrosigine Pump Challenge at the America’s ... The Arnold Sports Festival in Columbus, Ohio. The event ... 2015. , Nitrosigine is a patented ingredient of ... status; now affirmed as GRAS.^ It has been clinically ...
(Date:3/4/2015)... The report “Vasculitis – Pipeline Review, H1 ... Vasculitis. Vasculitis is a disease that features tenderness of ... is not known. Vasculitis can affect any body system ... can include fever, weight loss, tiredness, aches, pains, night ... limb. Vasculitis is treatable, but it is not curable. ...
(Date:3/4/2015)... The week of March 2nd - 8th ... Awareness Day being recognized on March 13th, the aim ... risks associated with sleep related illnesses, costing the United ... of America have turned to social media with an ... virally inspire conversation regarding the disease. , The ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... a worrisome public health issue worldwide. The rising prevalence ... economic and social burden in both developed and developing ... is projected to rise to 1.5 billion, equating to ... of these patients are forecast to come from the ...
(Date:3/4/2015)... Bird B Gone, the leader in ... now offers its popular plastic (polycarbonate) bird spike in ... bird deterrent is ready-to-use and comes in ... décor of the building or structure onto which it ... clear, light grey, brown, black and tan—make the spikes ...
Breaking Medicine News(10 mins):Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 2Health News:Nitrosigine® Challenges Fitness Enthusiasts at The Arnold to Get Pumped 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Vasculitis Therapeutics Pipeline H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 2Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 3Health News:Innovative Sleep Apnea Procedure Could Save US Healthcare System Billions 4Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 2Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 3Health News:Aging Population Drives Demand for Blood Pressure Monitoring & Measurement Instruments, According to a New Report by Global Industry Analysts, Inc. 4Health News:Plastic Bird Spikes Now Come in 7 Colors to Blend in With Their Surroundings 2
... world-renowned fragile X syndrome researcher, who was the first ... disorder, will be honored by the March of Dimes. ... Timmie Professor of Human Genetics and Charles Howard Candler ... as professor of biochemistry and pediatrics at Emory University ...
... of persons who smoked 20 or more cigarettes per day declined ... smoking 10 or more cigarettes a day, with these declines greater ... a study in the March 16 issue of JAMA . ... in the United States, consumption was typically 1 pack (about 20 ...
... by a new type of self-monitoring blood glucose sensor being ... Clinic in Arizona. More than 23 million people in ... leading cause of death in the United States. It contributes ... lower extremity amputations and other chronic conditions. Many people ...
... University doctor should be studied and copied as a way to ... problem of adding 40 million people to its health care system ... Health Team Model (FHT) could help ease the burden. "What we ... and efficient way of providing health care," says Walter Rosser, professor ...
... technique has demonstrated that it can measure the interactions between ... other biological molecules. These extremely difficult measurements can aid the ... percent of the 7,000 proteins in a human cell reside ... 60 to 70 percent of the signals that control the ...
... 15, 2011Since the first laparoscopic procedure was performed to ... University in St. Louis, this breakthrough minimally invasive technique ... This remarkable achievement is celebrated with a series of ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ...
Cached Medicine News:Health News:Fragile X researcher honored by March of Dimes 2Health News:Prevalence of heavy smokers in US decreases 2Health News:Prevalence of heavy smokers in US decreases 3Health News:New device holds promise of making blood glucose testing easier for patients with diabetes 2Health News:New device holds promise of making blood glucose testing easier for patients with diabetes 3Health News:New laser technique opens doors for drug discovery 2Health News:20th anniversary of first laparoscopic nephrectomy 2
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000CVA test face is used to evaluate both ... levels (high, 25% and 12.5%) of LogMAR acuity ... face as well as the two spatial frequencies ... most widely used for cataract documentation because eye ...
... is used widely for screening refractive surgery ... from 20/10 to 20/100 and one row ... ,The patient can be easily screened in ... contrast sensitivity. If a contrast sensitivity deficit ...
Medicine Products: